Citations

Clear

4207 citation(s) found for "Chen, Yu".

The Timing of Direct Oral Anticoagulant Usage Did Not Impact Outcomes Following Hip Arthroplasty for Femoral Neck Fractures
Chen, Xiao T. , Springer, Bryan D. , Borkar, Shalmali R. , Spaulding, Aaron , Yang, Linjun , Wyles, Cody C. , Bingham, Joshua S. , Wilke, Benjamin K. , Borkar, Shalmali , Porter, Steven B , Wilke, B K , Spaulding, Aaron , Wyles, Cody C , Bingham, Joshua S , Yang, Linjun , Porter, Steven B.

Mayo Clinic

Journal of Bone and Joint Surgery | July 10, 2025 | Volume: 107 | Issue: 16 | Pages: 1857-1866

10.2106/jbjs.24.01293 | PMID 40638713 Get It

Background: Orthopaedic surgeons routinely delay surgical management of femoral neck fractures in patients taking direct oral anticoagulants (DOACs) to decrease perioperative bleeding and associated complications. However, this practice contradicts the principles of hip fracture management, as early surgery is associated with morbidity and mortality benefits. The purpose of this study was to quantify the association of DOAC use and perioperative outcomes in patients who underwent hemiarthroplasty (HA) or total hip arthroplasty (THA) for femoral neck fractures. We hypothesized that early surgical intervention on a patient taking a DOAC medication would not lead to worse perioperative outcomes. Methods: A retrospective cohort study was conducted on 2,833 patients who underwent primary THA or HA for femoral neck fractures between December 31, 2017, and January 29, 2024, across our hospital system. The patients taking a DOAC were divided into 3 groups based on the time since the last DOAC intake: 1 day, 2 days, and ≥3 days. Propensity matching was performed 1:1, accounting for age, sex, Elixhauser Comorbidity Index, preoperative chronic kidney disease stage, preoperative hemoglobin, body mass index, and hospital type. Subanalyses utilizing linear and conditional logistic regression models were performed to assess differences in outcomes between the groups that had a DOAC withheld and the control groups. Results: The mean age of all patients was 81 ± 10 years, 1,805 patients (64%) were women, and 207 patients (7%) were taking a DOAC prior to surgery. Despite comparable preoperative and postoperative hemoglobin levels between the groups that had a DOAC withheld and the control groups (all p > 0.05), the patients who had a DOAC withheld for 1 day were more likely to receive a postoperative blood transfusion (23.1% compared with 0%; p = 0.002). This difference in transfusion rate was not observed in other cohorts. There were no differences in medical complications, reoperation, discharge disposition, or mortality between the groups that had a DOAC withheld and the matched controls at any time point. Conclusions: Delaying surgical management due to DOAC medications may be unnecessary in patients undergoing arthroplasty for femoral neck fractures. Consideration should be given to adjusting transfusion triggers to reduce unwarranted blood transfusions in patients taking a DOAC. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Razzo, Beatrice M. , Midha, Shonali , Portuguese, Andrew J. , Grajales‐Cruz, Ariel , Corraes, Andre De Menezes Silva , Costello, Patrick , Liu, Yuxin , Sperling, Adam S. , Nadeem, Omar , Dima, Danai , Cowan, Andrew J. , Afrough, Aimaz , Anderson, Larry D. , Goyal, Anmol , Ferreri, Christopher J. , Voorhees, Peter M. , Patel, Krina K. , Julian, Kelley , Forsberg, Peter A. , Susanibar-Adaniya, Sandra P. , Khouri, Jack , Raza, Shahzad , Vazquez‐Martinez, Mariola , Sborov, Douglas W. , Davis, James A. , Shune, Leyla , Bhurtel, Jenny , Hwang, Wei‐Ting , Sidana, Surbhi , Grajales-Cruz, Ariel F , De Menezes Silva Corraes, Andre , Banerjee, Rahul , Cowan, Andrew J , Afrough, Aimaz , Anderson, Larry D , Lieberman-Cribbin, Alex , Kaur, Gurbakhash , Goyal, Anmol , Atrash, Shebli , Ferreri, Christopher , Voorhees, Peter , Pasvolsky, Oren , Lee, Hans C , Patel, Krina , Julian, Kelley L , Forsberg, Peter A , Herr, Megan M. , Chhabra, Saurabh , Parrondo, Ricardo D , Lin, Yi , Chen, Anna , Susanibar-Adaniya, Sandra P , Khouri, Jack , Raza, Shahzad , Anwer, Faiz , Vazquez-Martinez, Mariola A , Castaneda Puglianini, Omar , Sborov, Douglas W , Davis, James A , Rossi, Adriana , Shune, Leyla , Bhurtel, Evguenia , Hwang, Wei-Ting , Hansen, Doris K , Sidana, Surbhi , Garfall, Alfred L , Richard, Shambavi , Nadeem, Omar , Dima, Danai , Sperling, Adam S , Portuguese, Andrew J , Banerjee, Rahul , Kaur, Gurbakhash , Atrash, Shebli , Pasvolsky, Oren , Lee, Hans C. , Chhabra, Saurabh , Lin, Yi , Anwer, Faiz , Puglianini, Omar Castañeda , Rossi, Adriana , Hansen, Doris K. , Garfall, Alfred L. , Richard, Shambavi

Mayo Clinic

Blood Cancer Discovery | July 9, 2025 | Volume: 6 | Issue: 6 | Pages: 561-571

10.1158/2643-3230.bcd-24-0354 | PMID 40629516 Get It

Abstract Teclistamab is an anti-CD3-/B-cell maturation antigen (BCMA) bispecific antibody approved for use in relapsed/refractory multiple myeloma. We undertook a retrospective study of post-approval, real-world outcomes with teclistamab in the US Multiple Myeloma Immunotherapy Consortium. Among 509 patients, 89% would have been ineligible for the MajesTEC-1 trial, primarily due to prior BCMA-directed therapy, cytopenias, or diminished performance status. Cytokine release syndrome occurred in 54% (1.4% grade ≥3) and immune effector cell–associated neurotoxicity syndrome in 11% (2.2% grade ≥3), with no fatal events. Infections occurred in 42% and contributed to death in 5%. Partial response (PR) or better was achieved in 53% and very good PR or better in 45%. With 10.1 months of median follow-up, the estimated median progression-free survival (PFS) was 5.8 months and 12-month overall survival was 61%. Independent predictors of less than very good PR and shorter PFS included BCMA-directed chimeric antigen receptor T-cell therapy in the previous 9 months, high disease burden, lymphopenia, and elevated ferritin. Significance: T cell–engaging bispecific antibodies such as teclistamab represent an important new treatment modality for multiple myeloma and other blood cancers. This study evaluates the real-world safety and efficacy of teclistamab, including its activity in populations not represented in the initial phase I/II study, and identifies clinical variables associated with treatment response. See related commentary by Zweegman et al., p. 542
Supporting the Deceased, Their Families, and Their Communities – Part 2: Practical Guidance for Building an Office of Decedent Affairs
Chambers, Meagan , Bartholow, Tanner, Parker, Zachary T., Peters, Kristina, Reichard, R. Ross , Tigard, Charles, Hooper, Jody E. , Benson, Paul , Davis, Ronnie, Cool, Robert, Beglarian, Ben, Mount, Sharon , Jackson, Nicole R. , Marshall, Desiree A. , Harcourt, Lisbeth, Wiley, LaTresa E., Comstock, Jessica, Hyland, Courtney, Harper, Holly , Priemer, David S. , Rapkiewicz, Amy , Rojiani, Amyn M. , Sanchez, Harold, Parker, Zachary T., Peters, Kristina, Luthringer, Daniel , Davis, Ronnie, Scherpelz, Kathryn P. , Sinard, John H. , Chen, Sonja

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 8, 2025 | Volume: 149 | Issue: 12 | Pages: 1077-1083

10.5858/arpa.2025-0094-oa | PMID 40626859 Get It

Context.— After-death care can be complicated and time-consuming for clinical staff, and frustrating for bereaved families. Delays and errors can have damaging legal and reputational consequences for hospitals. Offices of Decedent Affairs (ODAs) have been proposed as a solution, and their potential benefits have been described in several single institution reports. The literature lacks a contemporary and comprehensive review of existing ODAs and their approaches. Objective.— To describe the process of establishing a new ODA and to provide a snapshot of the spectrum of structure, function, and impact of existing ODAs in the United States. Design.— A survey was administered to 11 established ODAs spread across the continental United States. Programs were identified through the College of American Pathologists Autopsy Committee and a Medical Autopsy Listserv. Results.— Eleven ODAs returned the survey, representing more than 190 cumulative years of experience in decedent care in the hospital setting (median, 10 years). There was a wide range in staffing (both staff size and background) as well as scope of services offered. The median ratio of hospital deaths to full-time equivalent (FTE) staffing was 360 deaths per FTE. Respondents reported that ODAs unburden clinical providers and facilitate decedent management. Some respondents reported a quicker turnover of hospital beds and shorter intervals between pronouncement of death and autopsy. ODAs increased autopsy rates when the autopsy services were part of the ODA. Conclusions.— This survey provides practical information for hospitals considering establishing a new ODA and useful benchmarks for existing ODA programs.
Supporting the Deceased, Their Families, and Their Communities – Part 1: Why Establish an Office of Decedent Affairs
Chambers, Meagan , Bartholow, Tanner, Parker, Zachary T., Peters, Kristina, Reichard, R. Ross , Tigard, Charles, Hooper, Jody E. , Benson, Paul , Davis, Ronnie, Cool, Robert, Beglarian, Ben, Mount, Sharon , Jackson, Nicole R. , Marshall, Desiree A. , Harcourt, Lisbeth, Wiley, LaTresa E., Comstock, Jessica, Hyland, Courtney, Harper, Holly , Priemer, David S. , Rapkiewicz, Amy , Rojiani, Amyn M. , Sanchez, Harold, Parker, Zachary T., Peters, Kristina, Luthringer, Daniel , Davis, Ronnie, Scherpelz, Kathryn P. , Sinard, John H. , Chen, Sonja

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 8, 2025 | Volume: 149 | Issue: 12 | Pages: 1072-1076

10.5858/arpa.2025-0090-oa | PMID 40626861 Get It

Context.— Decedent Affairs Offices and Programs can serve as an avenue to assist medical centers in facilitating efficient and comprehensive decedent management, despite a paucity of literature on their roles, establishment, and efficacy. Objective.— To characterize the motivations and rationales for establishing Decedent Affairs Offices. Design.— A survey was administered to 11 established Decedent Affairs Offices/Programs, identified through the College of American Pathologists Autopsy Committee and a Medical Autopsy Listserv. The questions comprehensively cover establishment, operations, and outcomes data available by institution. Results.— Survey respondents reported the rationale for starting their programs and the benefits such offices can have. Conclusions.— Decedent Affairs Offices and Programs provide a useful option to medical centers to navigate the increasingly complex task of comprehensive decedent management. The present survey helps to delineate the similarities and differences between these programs at 11 institutions, to aid nascent programs in their establishment and growth over time.
Outcomes of Patients With Embolic Stroke of Undetermined Source Treated With Antiplatelet Agents or Anticoagulation
Siegler, James E. , Badillo‐Goicoechea, Elena , Penckofer, Mary , Eklund, Kelsey , Yaghi, Shadi , Stretz, Christoph , Lineback, Christina , Stamm, Brian , Peter, Shani , D’Souza, Marissa , Conyers, Frank, Khasiyev, Farid , Kerrigan, Deborah , Lewis, Skylar, Ali, Hamid , Nour, Hassan Aboul , Sharma, Richa, Glover, Patrick , Thompson, Sean, Alshaer, Qasem , Thottempudi, Neeharika, Melkumova, Emiliya , Chionatos, Rafail , Daniel, Jean-Philippe Auguste, Frankel, Michael , Dumitrașcu, Oana , Parikh, Parth , Doolittle, Charles, Yahnke, Ian, Sathya, Anvitha , Kang, Jieun , Kirchhoffer, Kaitlyn, Bowman, Anna, Smith, M. J., Asabere, Aaron, Shahrivari, Mahan, Sheibani, Nazanin , Krishnaiah, Balaji , Gaudio, Elizabeth, Rothstein, Aaron , Alvi, Muhammad M. , Annam, Saketh , Amankwah, Curtis , Kam, Wayneho , Abburi, Nandini , Rojas-Soto, Diana , Molaie, Amir , Khezri, Nicole, Zubair, Adeel , Abbasi, Mehdi , Coevering, Russell J. Van , Nedelcu, Simona , Herpich, Franziska , Chahien, Dalia, Sehgal, Siddharth, Liebeskind, David S. , Linares, Guillermo , Zha, Alicia , Sarkar, Monica , Xi, Romi, Nelson, Ashley, Qdais, Ahmad Abu, Kasab, Sami Al , Singh, Eesha , Patel, Vivek , Mehndiratta, Prachi , DeMarco, Alexis, Cucchiara, Brett , Omran, Setareh Salehi , Dubinski, Michael , Ackerman, Jiyoun, Thon, Jesse , Brown, Samantha , Siegler, James E , Goicoechea, Elena Badillo , Lineback, Christina M , Conyers, F Garrett , Aboul-Nour, Hassan , Sharma, Richa , Nahab, Fadi B , Glover, Patrick , Alshaer, Qasem N , de Havenon, Adam H , Melkumova, Emiliya , Chionatos, Rafail A , Jillella, Dinesh V , Frankel, Michael R , Dumitrascu, Oana M , Sathya, Anvitha , Smith, Matthew M , Brorson, James R , Elangovan, Cheran , Krishnaiah, Balaji , Sloane, Kelly L , Rothstein, Aaron , Alvi, Muhammad M , Kam, Wayneho , Abburi, Nandini , Farooqui, Mudassir , Molaie, Amir , Zubair, Adeel , Abbasi, Mehdi , Van Coevering, Russell J , Nedelcu, Simona , Liebeskind, David S. , Linares, Guillermo , Zha, Alicia , Abu Qdais, Ahmad , Al Kasab, Sami , Aziz, Yasmin , Mehndiratta, Prachi , Sharrief, Anjail , Cucchiara, Brett L , Salehi Omran, Setareh , Nguyen, Thanh N , Thon, Jesse , Yaghi, Shadi , Stretz, Christoph , Penckofer, Mary , Khasiyev, Farid , Brown, Samantha J , Eklund, Kelsey , Stamm, Brian , Daniel, Jean-Philippe Auguste , D'Souza, Marissa , Sharma, Richa , Thottempudi, Neeharika , Havenon, Adam de , Culbertson, Collin J , Jillella, Dinesh , Daniel, Jean-Philippe Auguste, Ro, Jennifer , Brown, Samantha, Doolittle, Charles, Brorson, James R. , Asabere, Aaron, Elangovan, Cheran , Chen, Lucia , Aziz, Yasmin , Nguyen, Thanh N. , Ackerman, Jiyoun

Mayo Clinic

Neurology | July 3, 2025 | Volume: 105 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000213876 | PMID 40609061 Get It

Multi‐Institutional Survey of 4‐Year Ultrasound Quality Control Findings
Long, Zaiyang , Russ, Megan , Larson, S, Holland, Mark, Lu, Zhengfeng , Kofler, Cameron , Chen, Jianfeng, Zagzebski, James A., Stickel, Jennifer R. , Dohatcu, Andreea, Stickel, Jennifer , Zhou, Wei , Li, Zhimin

Mayo Clinic

Journal of Ultrasound in Medicine | July 3, 2025 | Volume: 44 | Issue: 11 | Pages: 2103-2111

10.1002/jum.16763 | PMID 40607767 Get It

Objectives Periodic quality control (QC) testing of ultrasound (US) imaging systems is essential to ensure and maintain image quality and safety. The study aims to analyze QC findings from medical physics annual surveys of modern clinical US systems in a multi‐institutional survey. Methods QC results from annual surveys between 2018 and 2021 were retrospectively collected from 12 medical physicists from 11 institutions or consulting companies (hereafter referred to as sites). QC tests were classified as scanner‐ and transducer‐related tests, where scanner‐related tests also included evaluation of diagnostic workstation display monitors and routine QC programs if applicable. Test methodology and pass/fail criteria were established by each site. QC findings were defined as results requiring follow‐up action by service engineers, vendors, or other personnel. The percentage of annual findings was calculated for each site and averaged across the years of data contributed. Furthermore, findings across all sites were aggregated for an overall analysis. Results QC data from a total of 1069 scanner tests and 4542 transducer tests were collected. The average annual percentage of scanner‐related findings varied from 0 to 40.8% among all sites (first quartile 8.7%, median 18.2%, and third quartile 34.1%), while that of transducer‐related findings ranged between 0.5% and 19.9% (first quartile 3.9%, median 7.2%, and third quartile 14.5%). For scanner‐related tests, the top 3 categories of findings were associated with physical and mechanical integrity (171 findings, 74.7%), quantitative testing of the scanner display monitor (40 findings, 17.5%), and scanner port creating artifacts (10 findings, 4.4%). The top 3 findings for transducers related to uniformity and artifact (227 findings, 79.9%), physical and mechanical integrity (44 findings, 15.5%), and sensitivity in fundamental mode (9 findings, 3.2%). Conclusions Medical physics annual surveys revealed considerable actionable findings of modern US systems, which inform the status of current US QC practices in the United States and may guide future standardization and recommendation of QC tests.
Systemic Mastocytosis in 910 Patients: Prognostic Contribution of the International Consensus Classification in the Context of the Mayo Alliance Prognostic System
Aperna, Fnu, Abdelmagid, Maymona, Kumar, Mahesh, Butterfield, Joseph H. , Pongdee, Thanai , Yi, Cecilia Y. Arana , Patnaik, Mrinal M. , Arber, Daniel A. , Orazi, Attilio , Chen, Dong , Reichard, Kaaren K. , Gangat, Naseema , Pardanani, Animesh , Tefferi, Ayalew , Abdelmagid, Maymona G, Arana Yi, Cecilia Y , Patnaik, Mrinal , Chen, Dong , Arber, Daniel A , Orazi, Attilio , Yi, Cecilia Arana

Mayo Clinic

American Journal of Hematology | July 3, 2025 | Volume: 100 | Issue: 9 | Pages: 1566-1576

10.1002/ajh.27764 | PMID 40607735 Get It

ABSTRACTThe current study includes 910 patients with systemic mastocytosis (SM) seen at the Mayo Clinic from 1968 to 2024. The primary objective was to examine the prognostic contribution of the International Consensus Classification (ICC), in the context of the Mayo Alliance Prognostic System (MAPS) for SM. World Health Organization classification (WHO‐HAEM5) subcategories included (i) indolent/smoldering SM (ISM/SSM; N = 518), (ii) SM associated with another hematological neoplasm (SM‐AHN; N = 273), with the latter including both myeloid and lymphoid neoplasms, (iii) aggressive SM (ASM; N = 106), and (iv) WHO‐defined mast cell leukemia (MCL; N = 13), which included mast cells with both “mature” and “immature” morphology. The ICC‐defined subcategories were mostly similar with the exception that SM‐AHN was replaced by SM associated with another myeloid neoplasm (SM‐AMN; N = 235) and WHO‐defined MCL was replaced by ICC‐defined MCL (N = 8), which included only those with immature MC morphology. Overall survival (OS) was similar between WHO‐defined MCL (median 1.8 years) vs. SM‐AHN (median 2.3 years; p = 0.3) but significantly different between ICC‐defined MCL (median 0.08 years) vs. SM‐AMN (median 2.0 years; p < 0.01). Significant difference in OS was also apparent between ICC‐defined SM‐AMN and SM associated with lymphoid neoplasm (SM‐ALN; median 8.1 years; HR 3.4; p < 0.01). Multivariable analysis confirmed the inter‐independent prognostic contributions of both ICC‐defined morphologic subcategories and MAPS risk variables, including age > 60 years, anemia, alkaline phosphatase > ULN, and platelet count < 150 × 109/L (p < 0.03 in all instances); the same was not true for WHO‐HAEM5‐defined SM subcategories. The addition of mutational information into the multivariable model resulted in ousting anemia and inclusion of ASXL1 (p < 0.01), SRSF2 (p = 0.01), and NRAS (p = 0.01) mutations as additional risk factors. Classification of SM by ICC is prognostically more accurate, compared to WHO‐HAEM5, and strengthens the prognostic contribution of morphology to current clinical and molecular risk models.
Structurally disordered region in the SLC26A9 STAS-domain contains subregions that control SLC26A9 Cl - conductance
Holmes, Heather L. , Chang, Min‐Hwang , Decker, James W , Romero, Michael F. , Chen, An‐Ping

Mayo Clinic

Physiology | July 1, 2025 | Volume: 40 | Issue: S1 | Pages: No page available

10.1152/physiol.2025.40.s1.0967 Get It

SLC26A9 is a Cl - channel and electrogenic Cl - -HCO 3 ‑ exchanger found in several human epithelia, including the lung, intestine / GI tract, and kidney. SLC26 proteins are defined by a C-terminal, cytoplasmic sulfate transporter / anti-σ-domain (STAS). In mammals, several STAS domains have protein-protein interactions with the regulatory-region of CFTR (R-CFTR), the Cl - channel associated with cystic fibrosis. However, the functional consequences, i.e., regulatory effects (up/downregulation), of STAS-to-R-CFTR binding seem to differ by SLC26 member. Our prior work showed that the SLC26A9:CFTR interaction decreases SLC26A9 channel and exchange activity. If SLC26A9-STAS was replaced with SLC26A6-STAS, no inhibition of SLC26A9 conductance occurred when interacting with R-CFTR (PMID 19643730). Complete deletion of SLC26A9-STAS removed Cl - conductance. Thus, we hypothesized that a disordered loop within STAS is the likely interaction area, and therefore deleted this STAS-disordered loop (ΔLoop) to test this region’s functionality. We used a voltage clamp to measure Cl - currents (IV; conductance G calculated) in Xenopus laevis oocytes (n=10 / construct) injected with cRNA of ΔLoop and subcomponent areas of SLC26A9. Each construct contained a 3xFLAG tag such that stained oocytes from these constructs allowed determination of membrane expression. ΔLoop has three subregions: K/R rich, Middle, S/T rich. Both ΔLoop and ΔLoop(K/R) increase Cl - currents (and conductance) by 5x greater comparted to wild-type SLC26A9. Five amino acid extension of ΔLoop (N- or C-terminal) produces Cl - currents equivalent to ΔLoop deletion. However, 10 amino acid extension of ΔLoop (N- or C- direction) produces currents equivalent to WT-SLC26A9. Membrane localization indicates that ΔLoop and regional deletion constructs have similar membrane abundance to WT, while boundary deletions inhibit channel trafficking to the membrane. As ΔLoop(S/T) slightly increased conductance, the ordered S/T-rich motif [T 620 SVSYITFS 628 ] was examined for possible phosphorylation effects by serial alanine substitution. Each alanine substitution in the S/T-rich motif decrease SLC26A9 Cl - conductance vs WT-SLC26A9. However, for S623A the conductance decrease was due to minimal plasma membrane expression rather than apparent change of channel activity. Together these data suggest that the disordered loop is multifaceted and can maintain low conductance (autoinhibition) or by potential phosphorylation. As cystic fibrosis (CF) results from loss-of-function, trafficking or degradation mutations, the robust Cl - conductance from elimination of SLC26A9 autoinhibitory, disordered loop, presents an opportunity to supplement or replace Cl - conductance in CF tissues and potentially patients. R25-DK101405 This abstract was presented at the American Physiology Summit 2025 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC
Akahoshi, Yu , Inamoto, Yoshihiro , Spyrou, Nikolaos , Diniz, Márcio A. , Ayuk, Francis , Choe, Hannah , Doki, Noriko , Eto, Tetsuya, Etra, Aaron , Holler, Ernst , Kawakita, Toshiro , Tanaka, Takashi , Vášová, Ingrid, Ishimaru, Fumihiko , Fukuda, Takahiro, Chen, Yi‐Bin , Nakamura, Ryotaro , Ferrara, James L.M. , Kanda, Yoshinobu , Diniz, Marcio A , Doki, Noriko , Hexner, Elizabeth , Hogan, William J , Tanaka, Takashi , Yoshihara, Satoshi , Ishimaru, Fumihiko , Chen, Yi-Bin , Kanda, Junya , Nakamura, Ryotaro , Atsuta, Yoshiko , Levine, John E , Teshima, Takanori , Akahoshi, Yu , Nakasone, Hideki , Asada, Noboru , Eto, Tetsuya , Hexner, Elizabeth O. , Hiramoto, Nobuhiro , Hogan, William J. , Kataoka, Keisuke , Tanaka, Masatsugu , Uchida, Naoyuki , Levine, John E.

Mayo Clinic

Blood Advances | July 1, 2025 | Volume: 9 | Issue: 18 | Pages: 4640-4653

10.1182/bloodadvances.2025016233 | PMID 40590886 Get It

Abstract Overall response (OR) that combines complete (CR) and partial responses (PR) is the conventional end point for acute graft-versus-host disease (GVHD) trials. Because PR includes heterogeneous clinical presentations, reclassifying PR could produce a better end point. Patients in the primary treatment cohort from the Japanese Society for Transplantation and Cellular Therapy (JSTCT) were randomly divided into training and validation sets. In the training set, a classification and regression tree algorithm generated day 28 refined response (RR) criteria based on symptoms at treatment and day 28. We then evaluated RR for primary and second-line treatments, using the area under the receiver operating characteristic curve (AUC) and negative predictive value (NPV) for 6-month nonrelapse mortality as performance measures. RR considered patients with grade 0/1 at day 28 without additional treatment as responders. RR for primary treatment produced higher AUCs than OR with small improvement of NPVs in both validation sets: JSTCT (AUC, 0.73 vs 0.69 [P &lt; .001]; NPV, 92.0% vs 89.6% [P &lt; .001]) and the Mount Sinai Acute GVHD International Consortium (MAGIC; AUC, 0.71 vs 0.68 [P = .032]; NPV, 90.9% vs 89.8% [P = .009]). RR for second-line treatment produced similar AUCs but much higher NPVs than OR in both validation sets of JSTCT (AUC, 0.64 vs 0.63 [P = .775]; NPV, 74.5% vs 66.0% [P &lt; .001]) and MAGIC (AUC, 0.67 vs 0.64 [P = .105]; NPV, 86.8% vs 76.1% [P = .004]). Classifying persistent but mild skin symptoms as responses and residual lower gastrointestinal GVHD as nonresponses were major drivers in improving the prognostic performance of RR. Our externally validated day 28 RR would serve as a better end point than conventional criteria in future first- and second-line treatment trials.